37. A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 29 for the treatment or prophylaxis of hepatitis B virus infection.

38. A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 29, when manufactured according to a process of claim 30.

39. A method for the treatment or prophylaxis of hepatitis B virus infection, which method comprises administering a therapeutically effective amount of a compound as defined in any one of claims 1 to 29.